Nuveen Asset Management LLC Purchases 246,393 Shares of Privia Health Group, Inc. (NASDAQ:PRVA)

Nuveen Asset Management LLC grew its position in Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 19.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,488,979 shares of the company's stock after purchasing an additional 246,393 shares during the period. Nuveen Asset Management LLC owned about 1.24% of Privia Health Group worth $29,110,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. First Horizon Advisors Inc. increased its position in Privia Health Group by 53.8% in the 4th quarter. First Horizon Advisors Inc. now owns 1,807 shares of the company's stock worth $35,000 after purchasing an additional 632 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in Privia Health Group by 7,833.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,380 shares of the company's stock worth $47,000 after purchasing an additional 2,350 shares during the last quarter. Quadrant Capital Group LLC increased its position in Privia Health Group by 11.8% in the 4th quarter. Quadrant Capital Group LLC now owns 4,855 shares of the company's stock worth $95,000 after purchasing an additional 511 shares during the last quarter. Nisa Investment Advisors LLC increased its position in Privia Health Group by 185.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,999 shares of the company's stock worth $98,000 after purchasing an additional 3,249 shares during the last quarter. Finally, KBC Group NV increased its position in Privia Health Group by 48.1% in the 4th quarter. KBC Group NV now owns 5,012 shares of the company's stock worth $98,000 after purchasing an additional 1,627 shares during the last quarter. 94.48% of the stock is owned by institutional investors and hedge funds.

Privia Health Group Trading Up 2.0%

NASDAQ:PRVA traded up $0.46 during mid-day trading on Tuesday, hitting $23.32. 688,994 shares of the company's stock traded hands, compared to its average volume of 738,725. The firm has a 50 day moving average of $23.37 and a two-hundred day moving average of $22.71. Privia Health Group, Inc. has a 12 month low of $16.37 and a 12 month high of $26.09. The firm has a market capitalization of $2.84 billion, a price-to-earnings ratio of 233.22, a price-to-earnings-growth ratio of 3.47 and a beta of 0.87.

Insider Activity at Privia Health Group

In related news, CFO David Mountcastle sold 5,630 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $22.38, for a total transaction of $125,999.40. Following the completion of the sale, the chief financial officer now owns 179,676 shares in the company, valued at $4,021,148.88. This represents a 3.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Parth Mehrotra sold 15,100 shares of the stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $23.33, for a total value of $352,283.00. Following the sale, the chief executive officer now owns 454,281 shares of the company's stock, valued at approximately $10,598,375.73. The trade was a 3.22% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 51,579 shares of company stock worth $1,226,367 in the last 90 days. 10.70% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

PRVA has been the topic of several research reports. JMP Securities reaffirmed a "market outperform" rating and issued a $29.00 target price on shares of Privia Health Group in a research report on Monday, April 28th. Robert W. Baird upped their price target on Privia Health Group from $24.00 to $26.00 and gave the stock an "outperform" rating in a research note on Tuesday, April 15th. Needham & Company LLC reiterated a "buy" rating and set a $30.00 price target on shares of Privia Health Group in a research note on Thursday, April 10th. Canaccord Genuity Group upped their price target on Privia Health Group from $29.00 to $30.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Finally, Piper Sandler upped their price target on Privia Health Group from $25.00 to $40.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th. One research analyst has rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $27.46.

Privia Health Group Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.